Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

Video

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD